
https://www.science.org/content/blog-post/fast-plaques-slow-disease
# Fast Plaques in a Slow Disease (February 2008)

## 1. SUMMARY
This 2008 commentary reflects on the challenging state of Alzheimer's disease drug development, where standard of care had seen little advancement despite decades of research. The author highlights the particular difficulties of central nervous system programs: poor understanding of brain function, the blood-brain barrier as a drug delivery obstacle, the unique human susceptibility to Alzheimer's, and the lengthy, expensive clinical trials required. A key dispute mentioned is the ongoing debate about whether amyloid causes Alzheimer's—a question that persisted unresolved for years.

The piece focuses on a landmark Nature study from a Harvard group who implanted cranial windows in Alzheimer's-model mice to observe amyloid plaque formation in real time. Their striking finding was that amyloid plaques can form in hours—far more rapidly than anyone suspected—and that subsequent pathologies like microglia response occur later, offering evidence to potentially settle the amyloid debate.

The author concludes with concern that if similar rapid plaque dynamics occur in humans, therapeutic strategies targeting amyloid prevention or removal would face enormous challenges.

## 2. HISTORY
The subsequent years after this 2008 article were marked by continued failures in amyloid-targeting Alzheimer's therapies, casting doubt on whether the amyloid hypothesis alone explained the disease. Key developments include:

**Clinical Trial Failures (2008-2019):** Numerous anti-amyloid monoclonal antibodies—including bapineuzumab, solanezumab, crenezumab, and gantenerumab—failed in large Phase 3 trials despite showing some ability to reduce amyloid plaques. These failures cost billions and dampened enthusiasm for amyloid-centric approaches, suggesting that simply removing amyloid might be insufficient or too late.

**Mixed Late-Stage Results (2021-2024):** Biogen's aducanumab (Aduhelm) received controversial FDA approval in 2021 with conflicting data, limited evidence of clinical meaningfulness, and weak real-world uptake due to access and pricing (~$28,000/year). In contrast, lecanemab (Leqembi) gained full FDA approval in 2023 and traditional Medicare coverage after demonstrating modest cognitive benefit (27% slowing on CDR-SB over 18 months) with manageable ARIA (amyloid-related imaging abnormalities) side effects; by late 2024 it reached several tens of thousands of patients. Donanemab showed stronger amyloid clearance and clinical effects but also higher ARIA rates, with an expected FDA decision in 2025. These developments validated that amyloid reduction could produce measurable—albeit modest—clinical benefit.

**Growing Investment despite Continued Challenges:** Overall spending on Alzheimer's R&D grew, but many biotechs failed (e.g., Lundbeck terminated a Phase 2 tau antibody in 2023; TauRx's TRx-0237 didn't meet primary endpoints). Public policy evolved with broader CMS coverage for amyloid PET scans and Medicare determinations for approved anti-amyloid drugs. Lecanemab uptake remains moderate, reflecting modest efficacy and ARIA risks rather than broad paradigm shifts.

## 3. PREDICTIONS
- **Prediction in article**: "If this is even close to what's going on in humans, a therapy that tries to prevent amyloid formation or deposition is going to have some real work to do."
  - **Outcome**: Empirical results have partially validated this caution. Amyloid-targeting therapies did face significant hurdles, with most failing until lecanemab and donanemab offered modest success. However, even successful drugs show limited benefit—measurable but not transformative clinical slowing—suggesting that while amyloid reduction helps, it doesn't fully address the complex pathophysiology.

- **Implication**: The amyloid hypothesis held promise but required refined strategies (clearance before symptomatic stages) rather than total dismissal. The field learned that rapid plaque formation alone doesn't preclude therapeutic benefit, but benefits are modest, demanding adjuvant approaches and prevention trials.

## 4. INTEREST
Rating: **7/10**
The article captures a pivotal moment when insights into rapid plaque formation and new technologies were emerging, but it prefigures the long and difficult path ahead for amyloid therapeutics—a trajectory of expensive failures yielding modest benefits. It remains highly relevant as an early commentary anticipating the complex challenges that defined the next 15 years.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20080211-fast-plaques-slow-disease.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_